Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy: A preliminary study

Fawzy, Manal S.; Abdelghany, Ahmed A; Toraih, Eman A.; Mohamed, Abeer M

doi:10.17305/bjbms.2019.4533

Cited by 30 publications

(31 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, H19 was described as a significant prognostic marker in chronic liver disease patients with or without cirrhosis and HCC [105]. Consequently, as Fawzy et al [44] demonstrated in their study, H19 levels are significantly higher in plasma of T2D patients, though a receiver operating characteristics (ROC) analysis was not performed. Additionally, Tello-Flores et al [106] demonstrated in their study that the relative expression of serum H19 was two-fold higher among patients with impaired glycemic control when compared to diabetics with proper glucose control.…”

Section: Prognostic Potentialmentioning

confidence: 93%

“…Conclusively, evidence presented by Liu et al further underlined the magnitude of H19's input in hepatic insulin resistance development because it affects not only gluconeogenesis but also hepatic lipogenesis. Recently, Fawzy et al [44] found that H19 circulating levels were significantly increased among patients with T2D, which indicates that it may serve as a blood-based marker of hepatic insulin resistance, especially since its dysregulation has been described in a variety of metabolic disorders.…”

Section: Long-non-coding Rna H19mentioning

confidence: 99%

See 1 more Smart Citation

Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance

Pielok

Marycz

2020

IJMS

View full text Add to dashboard Cite

In the recent years, the prevalence of metabolic conditions such as type 2 Diabetes (T2D) and metabolic syndrome (MetS) raises. The impairment of liver metabolism resulting in hepatic insulin resistance is a common symptom and a critical step in the development of T2D and MetS. The liver plays a crucial role in maintaining glucose homeostasis. Hepatic insulin resistance can often be identified before other symptoms arrive; therefore, establishing methods for its early diagnosis would allow for the implementation of proper treatment in patients before the disease develops. Non-coding RNAs such as miRNAs (micro-RNA) and lncRNAs (long-non-coding RNA) are being recognized as promising novel biomarkers and therapeutic targets—especially due to their regulatory function. The dysregulation of miRNA and lncRNA activity has been reported in the livers of insulin-resistant patients. Many of those transcripts are involved in the regulation of the hepatic insulin signaling cascade. Furthermore, for several miRNAs (miR-802, miR-499-5p, and miR-122) and lncRNAs (H19 imprinted maternally expressed transcript (H19), maternally expressed gene 3 (MEG3), and metastasis associated lung adenocarcinoma transcript 1 (MALAT1)), circulating levels were altered in patients with prediabetes, T2D, and MetS. In the course of this review, the role of the aforementioned ncRNAs in hepatic insulin signaling cascade, as well as their potential application in diagnostics, is discussed. Overall, circulating ncRNAs are precise indicators of hepatic insulin resistance in the development of metabolic diseases and could be applied as early diagnostic and/or therapeutic tools in conditions associated with insulin resistance.

show abstract

Section: Prognostic Potentialmentioning

confidence: 93%

Section: Long-non-coding Rna H19mentioning

confidence: 99%

Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance

Pielok

Marycz

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…LncRNA GAS5 (growth-arrest specific transcript 5) is known as a cancer-suppressor that regulates cell growth, survival, and proliferation and is also involved in cancer [ 176 ] and T2DM [ 177 ] aetiology. Recently, it was shown that GAS5 is involved in PCOS and the associated IR pathogenesis.…”

Section: Long Noncoding Rnas—new Regulators Of Pcos Inflammationmentioning

confidence: 99%

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Dabravolski

Nikiforov

Eid

et al. 2021

IJMS

View full text Add to dashboard Cite

Polycystic ovarian syndrome (PCOS) is the most common endocrine–metabolic disorder affecting a vast population worldwide; it is linked with anovulation, mitochondrial dysfunctions and hormonal disbalance. Mutations in mtDNA have been identified in PCOS patients and likely play an important role in PCOS aetiology and pathogenesis; however, their causative role in PCOS development requires further investigation. As a low-grade chronic inflammation disease, PCOS patients have permanently elevated levels of inflammatory markers (TNF-α, CRP, IL-6, IL-8, IL-18). In this review, we summarise recent data regarding the role of mtDNA mutations and mitochondrial malfunctions in PCOS pathogenesis. Furthermore, we discuss recent papers dedicated to the identification of novel biomarkers for early PCOS diagnosis. Finally, traditional and new mitochondria-targeted treatments are discussed. This review intends to emphasise the key role of oxidative stress and chronic inflammation in PCOS pathogenesis; however, the exact molecular mechanism is mostly unknown and requires further investigation.

show abstract

“…These include LINC00523, LINC00994, 200 LY86‐AS1, HCG27_201, 201 THRIL, and SALRNA1 192 . Moreover, studies showed that levels of GAS5 lncRNA were decreased both in serum and in plasma of patients with T2D 197,202 . Lastly, the lncRNA HI‐LNC45 was found downregulated in human T2D islets 198 …”

Section: Lncrnas In Obesity‐associated Diseasesmentioning

confidence: 99%

“…Interestingly, LncRNA‐p3134 is highly expressed in serum's exosomes of patients with T2D as studies found that it is secreted by islet β‐cell 196 . Moreover, the lncRNA H19 was found upregulated in plasma of patients with T2D, 197 and the lncRNA KCNQ1OT1 was upregulated in T2D islets 198 . Evidences can also be obtained from murine models of the disease, as is the case of E330013P06, which was found upregulated firstly in macrophages of diet‐induced insulin‐resistant T2D mice and subsequently also found upregulated in monocytes from patients with T2D 199 …”

Section: Lncrnas In Obesity‐associated Diseasesmentioning

confidence: 99%

Role of long non‐coding RNAs in adipogenesis: State of the art and implications in obesity and obesity‐associated diseases

et al. 2021

View full text Add to dashboard Cite

Summary Obesity is an evolutionary, chronic, and relapsing disease that consists of a pathological accumulation of adipose tissue able to increase morbidity for high blood pressure, type 2 diabetes, metabolic syndrome, and obstructive sleep apnea in adults, children, and adolescents. Despite intense research over the last 20 years, obesity remains today a disease with a complex and multifactorial etiology. Recently, long non‐coding RNAs (lncRNAs) are emerging as interesting new regulators as different lncRNAs have been found to play a role in early and late phases of adipogenesis and to be implicated in obesity‐associated complications onset. In this review, we discuss the most recent advances on the role of lncRNAs in adipocyte biology and in obesity‐associated complications. Indeed, more and more researchers are focusing on investigating the underlying roles that these molecular modulators could play. Even if a significant number of evidence is correlation‐based, with lncRNAs being differentially expressed in a specific disease, recent works are now focused on deeply analyzing how lncRNAs can effectively modulate the disease pathogenesis onset and progression. LncRNAs possibly represent new molecular markers useful in the future for both the early diagnosis and a prompt clinical management of patients with obesity.

show abstract

Circulating long noncoding RNAs H19 and GAS5 are associated with type 2 diabetes but not with diabetic retinopathy: A preliminary study

Cited by 30 publications

References 35 publications

Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance

Non-Coding RNAs as Potential Novel Biomarkers for Early Diagnosis of Hepatic Insulin Resistance

Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome

Role of long non‐coding RNAs in adipogenesis: State of the art and implications in obesity and obesity‐associated diseases

Contact Info

Product

Resources

About